Horizon Pharma PLC (HZNP) Reaches $13.15 After 4.00% Up Move; Glenmede Trust Company Na Has Decreased Its Varian Medical Systems (VAR) Stake

August 7, 2017 - By Vivian Park

The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! About 6.95M shares traded or 98.57% up from the average. Horizon Pharma PLC (NASDAQ:HZNP) has declined 28.13% since August 7, 2016 and is downtrending. It has underperformed by 44.83% the S&P500.The move comes after 7 months positive chart setup for the $2.14B company. It was reported on Aug, 7 by Barchart.com. We have $13.68 PT which if reached, will make NASDAQ:HZNP worth $85.60M more.

Glenmede Trust Company Na decreased Varian Medical Systems Inc (VAR) stake by 19.5% reported in 2016Q4 SEC filing. Glenmede Trust Company Na sold 19,225 shares as Varian Medical Systems Inc (VAR)’s stock rose 13.68%. The Glenmede Trust Company Na holds 79,373 shares with $7.13M value, down from 98,598 last quarter. Varian Medical Systems Inc now has $8.85 billion valuation. The stock declined 0.33% or $0.32 reaching $96.29 per share. About 58,796 shares traded. Varian Medical Systems, Inc. (NYSE:VAR) has risen 29.46% since August 7, 2016 and is uptrending. It has outperformed by 12.76% the S&P500.

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Horizon Pharma had 32 analyst reports since September 9, 2015 according to SRatingsIntel. On Monday, November 23 the stock rating was reinitiated by Jefferies with “Buy”. On Tuesday, August 9 the stock rating was maintained by Citigroup with “Neutral”. Goldman Sachs initiated Horizon Pharma PLC (NASDAQ:HZNP) rating on Monday, June 6. Goldman Sachs has “Buy” rating and $24 target. The firm earned “Neutral” rating on Friday, December 9 by Mizuho. As per Tuesday, November 8, the company rating was maintained by Mizuho. The rating was upgraded by Mizuho on Friday, December 16 to “Buy”. The firm has “Buy” rating given on Tuesday, June 27 by Stifel Nicolaus. JMP Securities reinitiated the shares of HZNP in report on Wednesday, September 9 with “Mkt Outperform” rating. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Friday, October 9. Morgan Stanley upgraded Horizon Pharma PLC (NASDAQ:HZNP) on Monday, July 11 to “Equal-Weight” rating.

Investors sentiment decreased to 1.02 in Q4 2016. Its down 0.44, from 1.46 in 2016Q3. It worsened, as 40 investors sold Horizon Pharma PLC shares while 69 reduced holdings. 44 funds opened positions while 67 raised stakes. 134.44 million shares or 0.39% more from 133.91 million shares in 2016Q3 were reported. Systematic Fincl Limited Partnership has 0.06% invested in Horizon Pharma PLC (NASDAQ:HZNP). Fiera Capital owns 1.42 million shares or 0.13% of their US portfolio. Da Davidson owns 3,150 shares or 0% of their US portfolio. Blackrock Group Inc Ltd reported 106,963 shares. Brinker stated it has 12,980 shares. Bnp Paribas Arbitrage has 0% invested in Horizon Pharma PLC (NASDAQ:HZNP). Tiger Ltd Liability has 2.33% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 793,933 shares. Rothschild Asset Mngmt holds 1.20 million shares or 0.25% of its portfolio. Cornerstone Advsrs accumulated 847 shares. 27,171 were reported by Eaton Vance. First Trust Limited Partnership reported 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Silvercrest Asset Management Gru stated it has 11,560 shares. Creative Planning, a Kansas-based fund reported 84,148 shares. Css Ltd Liability Il holds 70,460 shares. Jw Asset Mngmt Ltd holds 5.46% or 507,075 shares in its portfolio.

Since February 28, 2017, it had 1 insider purchase, and 1 insider sale for $414,996 activity. Carey Robert sold $509,796 worth of stock. Shares for $94,800 were bought by GREY MICHAEL G.

Horizon Pharma Public Limited Company is a biopharmaceutical company. The company has market cap of $2.14 billion. The Firm is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. It currently has negative earnings. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Since February 22, 2017, it had 0 buys, and 14 selling transactions for $12.71 million activity. 3,589 shares were sold by BOSTROM SUSAN L, worth $326,902. 1,428 shares were sold by LARET MARK R, worth $147,761. On Monday, March 13 the insider KUO JOHN W sold $75,758. $5.64M worth of Varian Medical Systems, Inc. (NYSE:VAR) was sold by KENNEDY KOLLEEN T on Thursday, June 1. On Friday, June 9 the insider GUERTIN TIMOTHY E sold $1.65 million.

Among 10 analysts covering Varian Medical Systems Inc. (NYSE:VAR), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. Varian Medical Systems Inc. had 21 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by Brean Capital given on Thursday, April 28. Robert W. Baird maintained the shares of VAR in report on Wednesday, September 28 with “Neutral” rating. Barrington Research maintained Varian Medical Systems, Inc. (NYSE:VAR) rating on Friday, January 27. Barrington Research has “Outperform” rating and $98 target. The rating was upgraded by Citigroup on Monday, May 8 to “Buy”. Evercore downgraded the stock to “Sell” rating in Thursday, January 26 report. The stock of Varian Medical Systems, Inc. (NYSE:VAR) has “Neutral” rating given on Thursday, November 12 by Citigroup. The company was maintained on Monday, July 24 by RBC Capital Markets. The firm earned “Sector Perform” rating on Tuesday, December 22 by RBC Capital Markets. Barrington Research reinitiated Varian Medical Systems, Inc. (NYSE:VAR) on Tuesday, January 12 with “Outperform” rating. The stock of Varian Medical Systems, Inc. (NYSE:VAR) earned “Neutral” rating by Robert W. Baird on Tuesday, October 20.

Investors sentiment increased to 0.9 in 2016 Q4. Its up 0.01, from 0.89 in 2016Q3. It is positive, as 38 investors sold VAR shares while 188 reduced holdings. 59 funds opened positions while 144 raised stakes. 88.84 million shares or 2.22% less from 90.86 million shares in 2016Q3 were reported. Dekabank Deutsche Girozentrale holds 0.08% or 86,250 shares in its portfolio. Jpmorgan Chase & has invested 0% in Varian Medical Systems, Inc. (NYSE:VAR). 826,193 are owned by Invesco. Verition Fund Management Llc owns 5,595 shares for 0.04% of their portfolio. Pensionfund Dsm Netherlands invested in 34,000 shares. Highbridge Mgmt Ltd invested 0% in Varian Medical Systems, Inc. (NYSE:VAR). Greenleaf Tru reported 3,600 shares. United Fire Group Inc invested in 0.03% or 1,000 shares. New York-based Pzena Inv Limited Liability Corporation has invested 0% in Varian Medical Systems, Inc. (NYSE:VAR). Oppenheimer & Com Incorporated has 18,752 shares for 0.05% of their portfolio. Northeast Invest reported 2,260 shares or 0.02% of all its holdings. Millennium Mgmt Llc reported 221,931 shares. Lakeview Prtnrs Ltd Liability Co reported 3,066 shares. Tiaa Cref Investment Mgmt Ltd Liability Co owns 276,786 shares for 0.02% of their portfolio. 18,891 are held by Strs Ohio.

Glenmede Trust Company Na increased Hawaiian Electric Industries (NYSE:HE) stake by 17,420 shares to 21,970 valued at $726,000 in 2016Q4. It also upped Rayonier Advanced Materials (NYSE:RYAM) stake by 41,749 shares and now owns 42,214 shares. Cdw Corp (NASDAQ:CDW) was raised too.